1,400 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,400 shares of the company’s stock, valued at approximately $200,000.

Several other institutional investors have also recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. increased its position in shares of Novo Nordisk A/S by 32.7% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 8,769 shares of the company’s stock worth $1,252,000 after acquiring an additional 2,159 shares in the last quarter. Central Bank & Trust Co. bought a new stake in Novo Nordisk A/S during the 2nd quarter worth approximately $71,000. Lifestyle Asset Management Inc. raised its stake in shares of Novo Nordisk A/S by 19.1% in the second quarter. Lifestyle Asset Management Inc. now owns 2,433 shares of the company’s stock worth $347,000 after purchasing an additional 390 shares during the last quarter. MONECO Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 12.7% in the second quarter. MONECO Advisors LLC now owns 2,014 shares of the company’s stock valued at $287,000 after purchasing an additional 227 shares in the last quarter. Finally, Western Wealth Management LLC boosted its position in shares of Novo Nordisk A/S by 24.4% during the second quarter. Western Wealth Management LLC now owns 3,630 shares of the company’s stock valued at $518,000 after buying an additional 712 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on NVO shares. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target for the company. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 19th. Argus boosted their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, August 19th. Finally, BMO Capital Markets cut their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $145.17.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $136.97 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The firm has a market cap of $614.66 billion, a price-to-earnings ratio of 47.23, a P/E/G ratio of 1.33 and a beta of 0.41. Novo Nordisk A/S has a 52 week low of $86.96 and a 52 week high of $148.15. The firm’s 50-day simple moving average is $136.22 and its two-hundred day simple moving average is $131.57.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Monday, August 26th. Investors of record on Friday, August 16th will be issued a $0.5126 dividend. The ex-dividend date is Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.83%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.